GeoVax was using its HHS contract to develop its next-generation multi-antigen COVID-19 vaccine, which is in Phase IIb ...

The U.S. government continues to end contracts related to the $5 billion Project NextGen initiative, this time terminating ...

Peer-Reviewed Data Reinforces GeoVax's Multi-Antigen Strategy With GEO-CM02 and Supports Advancement of GEO-CM04S1 Clinical ...

Despite the PNG award termination, GeoVax anticipates a milestone-rich 2025 across its portfolio. The Company will continue to engage with government and industry partners, pursue clinical trial ...

EQS-News: GeoVax, Inc. / Key word (s): Financial GeoVax to Present Clinical Data at Upcoming April Industry Events 15.04.2025 / 15:04 CET/CEST The issuer is solely responsible for the content of ...

Good afternoon. And welcome everyone to the GeoVax Fourth Quarter Full Year 2024 Corporate Update Call. My name is Michelle and I will facilitate today’s call. With me are David Dodd ...

GEOVAX LABS ($GOVX) is expected to release its quarterly earnings data on Thursday, March 27th after market close, per Finnhub. Analysts are expecting revenue of ...

GeoVax Labs, Inc. (NASDAQ:GOVX – Free Report) – Investment analysts at Roth Capital issued their FY2029 EPS estimates for shares of GeoVax Labs in a research note issued on Friday, March 28th.

ATLANTA, GA - March 24, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious ...

Oncology, and Biosecurity Amid Strategic Program Developments ATLANTA, GA - April 16, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc.